Intervention not reported
fluoxetine:paroxetine · children and/or adolescents with depression
1 finding from 1 review
no estimate extracted
Studies not reported
Low
Intervention not reported
fluoxetine:sertraline · children and/or adolescents with depression
1 finding from 1 review
no estimate extracted
Studies not reported
Low
Intervention not reported
fluoxetine:venlafaxine · children and/or adolescents with depression
1 finding from 1 review
no estimate extracted
Studies not reported
Very low
Intervention not reported
mirtazapine:paroxetine · children and/or adolescents with depression
1 finding from 1 review
no estimate extracted
Studies not reported
Very low
Intervention not reported
mirtazapine:sertraline · children and/or adolescents with depression
1 finding from 1 review
no estimate extracted
Studies not reported
Very low
Intervention not reported
mirtazapine:venlafaxine · children and/or adolescents with depression
1 finding from 1 review
no estimate extracted
Studies not reported
Very low
Intervention not reported
mirtazapine:vilazodone · children and/or adolescents with depression
1 finding from 1 review
no estimate extracted
Studies not reported
Very low
Incidence of SAD (SIGH‐SAD score ≥ 20) ( · adults with a history of SAD who do not fulfil criteria for major depressive disorder
Bupropion XL probably leads to lower incidence of SAD (SIGH‐SAD score ≥ 20) compared with placebo (moderate certainty).
1 finding from 1 review
Overall rate of adverse events · adults with a history of SAD who do not fulfil criteria for major depressive disorder
Bupropion XL showed no clear difference in overall rate of adverse events compared with placebo (moderate certainty).
1 finding from 1 review
Headache · adults with a history of SAD who do not fulfil criteria for major depressive disorder
Bupropion XL probably leads to higher headache compared with placebo (moderate certainty).
1 finding from 1 review
Insomnia · adults with a history of SAD who do not fulfil criteria for major depressive disorder
Bupropion XL may leads to higher insomnia compared with placebo (low certainty).
1 finding from 1 review
Nausea · adults with a history of SAD who do not fulfil criteria for major depressive disorder
Bupropion XL may leads to higher nausea compared with placebo (low certainty).
1 finding from 1 review
Diarrhoea · adults with a history of SAD who do not fulfil criteria for major depressive disorder
Bupropion XL showed no clear difference in diarrhoea compared with placebo (low certainty).
1 finding from 1 review
Withdrawals due to adverse events · adults with a history of SAD who do not fulfil criteria for major depressive disorder
Bupropion XL showed no clear difference in discontinuation due to adverse events compared with placebo (low certainty).
1 finding from 1 review
Depression at endpoint · patients with depression and dementia
1 finding from 1 review
Number of responders · patients with depression and dementia
Antidepressant treatment showed no clear difference in number of responders (ITT) at 6 to 12 weeks compared with placebo (low certainty).
1 finding from 1 review
Remission · patients with depression and dementia
Antidepressant treatment probably leads to higher number of patients with remission (ITT) at 6 to 12 weeks compared with placebo (moderate certainty).
1 finding from 1 review
Cognitive function · patients with depression and dementia
1 finding from 1 review
Activities of daily living · patients with depression and dementia
1 finding from 1 review
Dropout · patients with depression and dementia
Antidepressant treatment probably leads to higher number of dropouts at 6 to 13 weeks compared with placebo (moderate certainty).
1 finding from 1 review